Mounting evidence shows the endogenous opioid system is a potential therapeutic target for mood disorders, yet questions remain.
Cornel N. Stanciu, MD, MRO
As the COVID-19 pandemic continues to affect the country, SAMHSA and the DEA allow for flexibility in addressing the needs of patients with opioid use disorder.
Psychiatrists are exploring ways to best serve their patients while complying with the medicolegal restrictions of the coronavirus. Here: approaches to best leverage telemedicine for patients with ADHD.
Chronotherapy presents a unique tool to add to the armamentarium of available modalities for management of non-seasonal depression. Clinicians should be familiar with its application and be able to implement it in recalcitrant sufferers.
This research update underscores the need to be well versed in the data in order to have meaningful conversations with our patients who are cannabis users or contemplate use.
Public endorsement for potential benefits of the marijuana plant is at an all-time high, even in vulnerable populations, such as pregnant women.
This CME discusses the opioid-like effects of loperamide and kratom and raises awareness of potential dangers associated with use.
More than 6 out of 10 deaths involve prescribed opioids. The authors address guidelines for who should (and who should not) receive a naloxone prescription.
The authors use a 3-step process to identify and evaluate published research with findings that are ready for—and that have a direct bearing on—clinical practice.